FDA cites as "potential safety issue" liver failure with Sutent
This article was originally published in Scrip
Executive Summary
The US FDA is investigating a "potential signal of a serious risk/new safety information" relating to Pfizer's anticancer Sutent (sunitinib) and liver failure, according to its latest quarterly list of safety probes. The signal was identified from the Adverse Event Reporting System (AERS) database between January and March 2009.